dc.contributor.author | Dampalla, Chamandi S. | |
dc.contributor.author | Rathnayake, Athri D. | |
dc.contributor.author | Perera, Krishani Dinali | |
dc.contributor.author | Jesri, Abdul Rahman M. | |
dc.contributor.author | Nguyen, Harry Nhat | |
dc.contributor.author | Miller, Matthew J. | |
dc.contributor.author | Thurman, Hayden A. | |
dc.contributor.author | Zheng, Jian | |
dc.contributor.author | Kashipathy, Maithri M. | |
dc.contributor.author | Battaile, Kevin P. | |
dc.contributor.author | Lovell, Scott | |
dc.contributor.author | Perlman, Stanley | |
dc.date.accessioned | 2022-01-15T21:07:42Z | |
dc.date.available | 2022-01-15T21:07:42Z | |
dc.date.issued | 2021-12-01 | |
dc.identifier.citation | J. Med. Chem. 2021, 64, 24, 17846–17865 Publication Date:December 5, 2021 https://doi.org/10.1021/acs.jmedchem.1c01037 | en_US |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.uri | https://doi.org/10.1021/acs.jmedchem.1c01037 | |
dc.identifier.uri | https://soar.wichita.edu/handle/10057/22430 | |
dc.description | This article is made available via the ACS COVID-19 subset for unrestricted RESEARCH re-use
and analyses in any form or by any means with acknowledgement of the original source.
These permissions are granted for the duration of the World Health Organization (WHO)
declaration of COVID-19 as a global pandemic. | en_US |
dc.description.abstract | The COVID-19 pandemic is having a major impact on public health worldwide, and there is an urgent need for the creation of an armamentarium of effective therapeutics, including vaccines, biologics, and small-molecule therapeutics, to combat SARS-CoV-2 and emerging variants. Inspection of the virus life cycle reveals multiple viral- and host-based choke points that can be exploited to combat the virus. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for therapeutic intervention, and the design of inhibitors of the protease may lead to the emergence of effective SARS-CoV-2-specific antivirals. We describe herein the results of our studies related to the application of X-ray crystallography, the Thorpe–Ingold effect, deuteration, and stereochemistry in the design of highly potent and nontoxic inhibitors of SARS-CoV-2 3CLpro. | en_US |
dc.description.sponsorship | This research was supported, in part, by grants from the National
Institutes of Health (NIH) (R01 AI109039 to K.-O.C). Use of
the University of Kansas Protein Structure Laboratory was
supported by a grant from the National Institute of General
Medical Sciences (P30GM110761) of the NIH. Support for the
NMR instrumentation was provided by NIH Shared Instrumentation Grant # S10RR024664 and NSF Major Research
Instrumentation Award #1625923. Use of the IMCA-CAT
beamline 17-ID at the Advanced Photon Source was supported
by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon
Source was supported by the U.S. Department of Energy, Office
of Science, Office of Basic Energy Sciences under contract no.
DE-AC02-06CH11357. This research used the AMX beamline
of the National Synchrotron Light Source II, a U.S. Department
of Energy (DOE) Office of Science User Facility operated for
the DOE Office of Science by Brookhaven National Laboratory
under Contract No. DE-SC0012704. The Center for BioMolecular Structure (CBMS) was primarily supported by the
National Institutes of Health, the National Institute of General
Medical Sciences (NIGMS) through a Center Core P30 Grant
(P30GM133893), and the DOE Office of Biological and
Environmental Research (KP1605010). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | American Chemical Society | en_US |
dc.relation.ispartofseries | Journal of Medicinal Chemistry; | |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Assays | en_US |
dc.subject | Inhibitors | en_US |
dc.subject | Alcohols | en_US |
dc.subject | Peptides and proteins | en_US |
dc.title | Structure-guided design of potent inhibitors of SARS-CoV-2 3CL protease: Structural, biochemical, and cell-based studies | en_US |
dc.type | Article | en_US |
dc.rights.holder | Copyright © 2021 American Chemical Society | en_US |